Leqembi gains approval for Alzheimer’s treatment in Israel
The approval of Leqembi (generic name: Lecanemab) in Israel marks a significant milestone, as Israel becomes the sixth territory to endorse the drug for Alzheimer’s treatment after the
Merck has initiated commercial manufacturing of its first Good Manufacturing Practices (GMP)-compliant manufacturing line for cell culture media (CCM) in China.
The funding will support ongoing clinical trials for X-Linked Retinitis Pigmentosa (XLRP) and advance the company’s Dry Age-related Macular Degeneration (dAMD) programme. The investment round included contributions from